EUVIMEDEUVIMED entdecken
Crossref

Real world data on dual BLyS/APRIL inhibition with telitacicept for lupus nephritis

Jingjing Jin, Meng Tan, Ying Tan, Minghui Zhao

Nephrology Dialysis Transplantation · 29.08.2025 · 40 (9) · 1775-1785

DOI: 10.1093/ndt/gfaf049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 06.03.2025. Verfasst von Jingjing Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University, Key Laboratory of Renal Disease…. Hauptthemen laut MEDLINE: Lupus Nephritis, B-Cell Activating Factor, Tumor Necrosis Factor Ligand Superfamily Member 13. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Beijing Natural Science Foundation, Capital's Funds for Health Improvement and Research, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to evaluate the efficacy and safety of telitacicept for the treatment of lupus nephritis (LN) in real-world clinical practice.

Methods

Adult patients with LN receiving additional telitacicept at 80/160 mg once per week were recruited, while patients receiving only standard therapy were included as the control group using a 1:1 propensity score–matching approach. The primary outcomes were the proportions of patients achieving complete renal response (CRR) and primary efficacy renal response (PERR).

Results

Forty-four patients in both the control and telitacicept groups were enrolled, with median follow-up periods of 10.78 ± 3.37 and 10.5 ± 3.78 months, respectively. Compared with the control group, a significant improvement was observed in the proportion of patients achieving CRR (11.36% vs 29.55%, P = .034) and PERR (45.45% vs 68.18%, P = .031) in the telitacicept group at the last visit. Median proteinuria was reduced by 0.97 g/day (63.82%) from baseline in the telitacicept group, compared with a reduction of 0.31 g/day (25.31%) in the control group. Additionally, the telitacicept group showed notable treatment responses in the median SLE Disease Activity Index-2000 score, Physician's Global Assessment score and glucocorticoid dose reduction. Subgroup analysis revealed that telitacicept exhibited a more prominent therapeutic effect in patients with type V LN and those with proteinuria exceeding 3 g/day. Telitacicept was well tolerated, and the incidence of adverse events was similar between the two groups.

Conclusions

LN patients receiving additional telitacicept treatment demonstrated better disease remission, particularly in those with type V LN and proteinuria ≥3 g/day, with a favorable safety profile in real-world clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisB-Cell Activating FactorTumor Necrosis Factor Ligand Superfamily Member 13HumansFemaleMaleAdultFollow-Up StudiesPrognosisMiddle AgedYoung AdultGlomerular Filtration RateRetrospective StudiesRecombinant Fusion Proteins

Stichwörter der Autor:innen

efficacylupus nephritissafetytelitacicept

Substanzen

B-Cell Activating FactorTumor Necrosis Factor Ligand Superfamily Member 13TNFSF13B protein, humanTNFSF13 protein, humantelitaciceptRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University, Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Diseas…
  • Departments of Nephrology, The Fourth Hospital of Hebei Medical University, Hebei Key Laboratory of Vascular Calcification in Kidney Disease, Hebei Clinical Research Center for Chronic Kidney Disease, Shijiazhuang, Hebe…

Förderung

  • Beijing Natural Science Foundation
  • Capital's Funds for Health Improvement and Research
  • National High Level Hospital Clinical Research Funding
  • Fundamental Research Funds for the Central Universities
  • CAMS Innovation Fund for Medical Sciences
  • Peking University First Hospital Cross-Research Project
  • National Key Research and Development Program of China
  • Medical Science Research Project of Hebei

Zitieren

APA

Jin, J., Tan, M., Tan, Y., & Zhao, M. (2025). Real world data on dual BLyS/APRIL inhibition with telitacicept for lupus nephritis. Nephrology Dialysis Transplantation, 40(9), 1775-1785. https://doi.org/10.1093/ndt/gfaf049

Vancouver

Jin J, Tan M, Tan Y, Zhao M. Real world data on dual BLyS/APRIL inhibition with telitacicept for lupus nephritis. Nephrology Dialysis Transplantation. 2025;40(9):1775-1785. doi:10.1093/ndt/gfaf049

BibTeX
@article{Jin2025,
  author = {Jin, Jingjing and Tan, Meng and Tan, Ying and Zhao, Minghui},
  title = {Real world data on dual BLyS/APRIL inhibition with telitacicept for lupus nephritis},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  volume = {40},
  number = {9},
  pages = {1775--1785},
  doi = {10.1093/ndt/gfaf049}
}
Kostenlos starten →